The Employer's Guide to Medical Cannabis

A framework for workforce health, cost management and benefits innovation.

A practical playbook for self-funded employers, benefits brokers, TPAs and health plans — how to turn unmanaged cannabis use into a governed, clinically guided benefit with defined oversight and measurable outcomes.

Employers guide to medical cannabis
Trusted by 700K+ Patients

Trusted by 700K+ Patients

Clinically Backed & Peer-Reviewed

Clinically Backed & Peer-Reviewed

Available Nationally

Available Nationally

Why This Belongs on Your Benefits Roadmap

Medical cannabis now intersects cost, chronic-condition management, workforce wellbeing and compliance — the same pressures driving every benefits decision you make.

$18,500

Rising cost pressure

Projected 2026 average cost of employer-sponsored health benefits per employee — up 6.7% and climbing. 84% of employers rank cost management in their top three priorities.

79%

A path away from opioids

Share of medical cannabis patients who report reducing or eliminating opioids; 60%+ replace prescription drugs. Non-opioid pain management is now a strategic priority.

21.5%

A governance gap

Of past-12-month consumers used cannabis at or within two hours of work. Unmanaged use sits outside your health plan — the guide shows how to bring it into a governed structure.

What’s Inside the Guide

Chapter I

Why It’s Now an Employer Issue

62M Americans report cannabis use and 88% favor legalization. Why medical cannabis has moved from consumer behavior to a benefits question for HR, brokers and health plans.

Chapter II

The Cost of Unmanaged Use

How fragmented, unmanaged use creates safety gaps and preventable spend — plus emerging workers’-comp evidence (−20% benefit receipt, −$21.98 annual WC income after reform).

Chapter III

Governance & Workforce Risk

How to offer access without weakening workplace standards — the two boundaries that keep confidential clinical care separate from fit-for-duty policy.

Chapter IV

The Leafwell Framework

The clinically guided operating model — employer sets program design and guardrails; licensed providers make clinical decisions. Chronic-pain outcomes: −2.0pp urgent care, −3.2pp ED visits.

Chapter V · Conclusion

Position employer-sponsored medical cannabis not as an unstructured reimbursement experiment, but as a governed clinical benefit with defined oversight, credible measurement and clear boundaries.

Get the full guide →

EF
About the Author

Emily Fisher, Founder & CEO of Leafwell

Emily leads Leafwell’s mission to integrate medical cannabis into mainstream healthcare through evidence-based, physician-led care. This guide distills that work into a practical framework for the employers, brokers and health plans building the next generation of benefits.

Get your free copy

Complete the short form below to download The Employer’s Guide to Medical Cannabis by Emily Fisher — instant access, no cost.

Download the free guide →